N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose : An amino trisaccharide that is the carbohydrate portion of ganglioside GM3. It comprises a linear sequence of alpha-N-acetylneuraminyl, beta-D-galactosyl and beta-D-glucose residues linked (2->3) and (1->4). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5288424 |
| CHEMBL ID | 3764379 |
| CHEBI ID | 59226 |
| Synonym |
|---|
| alpha-n-acetylneuraminyl-(2->3)-beta-d-galactosyl-(1->4)-beta-d-glucose |
| alpha-neup5ac-(2->3)-beta-d-galp-(1->4)-beta-d-glcp |
| (2->3')-alpha-sialyllactose |
| gm3 carbohydrate moiety |
| neu5aca2-3galb1-4glcb |
| alpha-neu5ac-(2->3)-beta-d-gal-(1->4)-beta-d-glc |
| alpha-neu5ac-(2->3)-beta-d-gal-(->4)-d-glc |
| (2->3')-a-sialyllactose |
| alpha-neu5ac-(2->3)-beta-delta-gal-(1->4)-delta-glc |
| a-neu5ac-(2->3)-b-d-gal-(1->4)-d-glc |
| n-acetyl-alpha-neuraminyl-(2->3)-beta-d-galactosyl-(1->4)-beta-d-glucose |
| CHEBI:59226 |
| neu5acalpha2-3galbeta1-4glcbeta |
| 5-acetamido-3,5-dideoxy-d-glycero-alpha-d-galacto-non-2-ulopyranonosyl-(2->3)-beta-d-galactopyranosyl-(1->4)-beta-d-glucopyranose |
| 3AP7 |
| CHEMBL3764379 , |
| 4LBO |
| 4LBL |
| 3'-alpha-sialyl-beta-lactose |
| beta-d-glucopyranose, o-(n-acetyl-alpha-neuraminosyl)-(2->3)-o-beta-d-galactopyranosyl-(1->4)- |
| H668G020YH , |
| unii-h668g020yh |
| 64839-33-4 |
| sialyllactose, (beta-d-glucopyranose)- |
| Q27104848 |
| 3'-.alpha.-sialyl-.beta.-lactose |
| .beta.-d-glucopyranose, o-(n-acetyl-.alpha.-neuraminosyl)-(2->3)-o-.beta.-d-galactopyranosyl-(1->4)- |
| sialyllactose, (.beta.-d-glucopyranose)- |
| bdbm50230648 |
| Role | Description |
|---|---|
| mammalian metabolite | Any animal metabolite produced during a metabolic reaction in mammals. |
| epitope | The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-D-glucose | An amino trisaccharide that comprises of a linear sequence of alpha-N-acetylneuraminyl, beta-D-galactosyl and D-glucose residues linked (2->3) and (1->4). It is found in human milk. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Galectin-8 | Homo sapiens (human) | Kd | 2.3000 | 2.3000 | 2.3000 | 2.3000 | AID1675450 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cellular response to virus | Galectin-8 | Homo sapiens (human) |
| xenophagy | Galectin-8 | Homo sapiens (human) |
| lymphatic endothelial cell migration | Galectin-8 | Homo sapiens (human) |
| cell adhesion | Sialic acid-binding Ig-like lectin 7 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| integrin binding | Galectin-8 | Homo sapiens (human) |
| protein binding | Galectin-8 | Homo sapiens (human) |
| carbohydrate binding | Galectin-8 | Homo sapiens (human) |
| protein binding | Sialic acid-binding Ig-like lectin 7 | Homo sapiens (human) |
| carbohydrate binding | Sialic acid-binding Ig-like lectin 7 | Homo sapiens (human) |
| signaling receptor activity | Sialic acid-binding Ig-like lectin 7 | Homo sapiens (human) |
| sialic acid binding | Sialic acid-binding Ig-like lectin 7 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular space | Galectin-8 | Homo sapiens (human) |
| cytoplasm | Galectin-8 | Homo sapiens (human) |
| cytosol | Galectin-8 | Homo sapiens (human) |
| membrane | Galectin-8 | Homo sapiens (human) |
| cytoplasmic vesicle | Galectin-8 | Homo sapiens (human) |
| cytoplasm | Galectin-8 | Homo sapiens (human) |
| plasma membrane | Sialic acid-binding Ig-like lectin 7 | Homo sapiens (human) |
| plasma membrane | Sialic acid-binding Ig-like lectin 7 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2011 | The Journal of biological chemistry, Apr-01, Volume: 286, Issue:13 | Galectin-8-N-domain recognition mechanism for sialylated and sulfated glycans. |
| AID1278507 | Binding affinity to Influenza A virus (A/New Caledonia/20/99 (H1N1)) H1 hemagglutinin after 2 hrs by avidin-biotin-peroxidase complex method | 2016 | Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5 | Heptapeptide ligands against receptor-binding sites of influenza hemagglutinin toward anti-influenza therapy. |
| AID1427030 | Binding affinity to human IgG1-fused Siglec-7-Fc assessed as inhibition of Siglec-7-Fc binding to RBC preincubated for 10 mins followed by RBC addition measured after 20 mins by FACS analysis | 2017 | Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3 | Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune Evasion. |
| AID1427033 | Binding affinity to human IgG1-fused Siglec-7-Fc measured after 2.5 hrs by ELISA | 2017 | Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3 | Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune Evasion. |
| AID1427040 | Binding affinity to human IgG1-fused Siglec-7-Fc | 2017 | Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3 | Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune Evasion. |
| AID1278508 | Binding affinity to Influenza A virus (A/Wyoming/03/2003(H3N2)) H3 hemagglutinin after 2 hrs by avidin-biotin-peroxidase complex method | 2016 | Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5 | Heptapeptide ligands against receptor-binding sites of influenza hemagglutinin toward anti-influenza therapy. |
| AID1675450 | Binding affinity to N-terminal domain of human galectin-8 (8-154 residues) by ITC assay | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Rational Design and Synthesis of Methyl-β-d-galactomalonyl Phenyl Esters as Potent Galectin-8 |
| AID1278509 | Binding affinity to Influenza A virus (A/Aichi/2/68(H3N2)) H3 hemagglutinin after 2 hrs by NMR method | 2016 | Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5 | Heptapeptide ligands against receptor-binding sites of influenza hemagglutinin toward anti-influenza therapy. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2014 | Journal of molecular biology, Apr-03, Volume: 426, Issue:7 | Galectin-3 interactions with glycosphingolipids. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||